Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 25 peer-reviewed journal articles Updated
Pediatric Neurology

Treating Dravet Syndrome: Medications and Beyond

At a Glance

Dravet syndrome requires specialized treatment because standard seizure drugs like sodium channel blockers can severely worsen symptoms. Effective management relies on specific FDA-approved medications like Fenfluramine, Stiripentol, and Epidiolex, alongside options like the ketogenic diet or VNS.

Managing Dravet syndrome requires a specialized approach because the brain’s chemistry is unique. Traditional epilepsy treatments that work for other children can be ineffective or even dangerous for a child with Dravet syndrome. The goal of treatment is seizure reduction and improving quality of life [1][2]. While complete seizure freedom is rare, modern treatments can significantly reduce the “seizure burden” and help your child be more present and engaged [3][4].

*** DANGER: Medications to Avoid ***

This is the most critical information for a newly diagnosed family. Certain medications can significantly worsen seizures in Dravet syndrome [5][6]. Because the SCN1A mutation already makes the brain’s “brakes” (sodium channels) weak, drugs that further block these channels disable those brakes, leading to more frequent and severe seizures [7][5].

Commonly contraindicated medications include:

  • Sodium Channel Blockers: Carbamazepine (Tegretol), Oxcarbazepine (Trileptal), Lamotrigine (Lamictal), Phenytoin or Fosphenytoin (Dilantin).
  • Other Medications to Avoid: Vigabatrin (Sabril). While this works on a different pathway (GABA), it is also known to worsen myoclonic or absence seizures in Dravet syndrome [5].

If your child is currently taking any of these, do not stop them abruptly, but contact your pediatric epileptologist immediately to discuss a safe transition [6][8].

The “Big Three” FDA-Approved Treatments

In recent years, three medications have emerged as the standard of care for reducing convulsive seizures in Dravet syndrome.

  1. Fenfluramine (Fintepla): This medication has shown some of the most significant results in clinical trials [9]. It works by interacting with serotonin receptors and the sigma-1 receptor to stabilize brain activity [10][11]. Because older versions of this drug (used for weight loss) were linked to heart issues, children on Fintepla receive regular ultrasounds of the heart (echocardiograms) as a safety precaution [9][12].
  2. Stiripentol (Diacomit): This drug is often used alongside clobazam and valproate [13]. It works in two ways: it directly increases the brain’s “calming” signals (GABA) and it slows down how the body breaks down other seizure medications, making them more effective [14][15].
  3. Cannabidiol (Epidiolex): This is a highly purified, pharmaceutical-grade CBD oil [16]. It does not cause a “high” but interacts with several pathways in the brain to reduce electrical excitability [17][18]. It is often well-tolerated and can be added to other medication regimens [19].

Non-Medication Therapies

When medications alone are not enough, your medical team may recommend these “hardware” or “fuel” changes:

  • The Ketogenic Diet: This is a high-fat, low-carbohydrate medical diet that forces the brain to burn ketones instead of glucose for fuel [20]. This change in metabolism has a stabilizing effect on brain cells and has been shown to reduce seizures in many children with Dravet [21][20]. This must be strictly supervised by a specialized Neuromuscular Dietitian and should never be attempted at home independently [22].
  • Vagus Nerve Stimulation (VNS): This is a small device, similar to a pacemaker, implanted under the skin of the chest [23]. It sends regular, mild pulses of electrical energy to the brain via the vagus nerve to help “reset” the brain’s electrical activity [23][24].

Emerging Options

Doctors are also exploring promising disease-modifying therapies, such as antisense oligonucleotides (ASOs) and targeted gene therapies. Unlike standard medications that merely try to stop the electrical storm, these therapies aim to address the underlying genetic issue of the SCN1A mutation directly [25]. Your specialist can help you determine if your child is a candidate for any ongoing clinical trials.

Common questions in this guide

Which seizure medications should be avoided in Dravet syndrome?
Children with Dravet syndrome should avoid sodium channel blockers like carbamazepine, oxcarbazepine, lamotrigine, and phenytoin. The medication vigabatrin should also be avoided, as these drugs can significantly worsen seizures by further weakening the brain's electrical brakes.
What are the primary medications used to treat Dravet syndrome?
The standard of care typically includes Fenfluramine (Fintepla), Stiripentol (Diacomit), and Cannabidiol (Epidiolex). These specialized medications are FDA-approved to help stabilize brain activity and reduce the frequency of convulsive seizures in Dravet syndrome.
Are there non-medication treatments for Dravet syndrome?
Yes, when medications are insufficient, doctors may recommend the ketogenic diet, which is a strict medical diet that changes how the brain fuels itself. Another option is Vagus Nerve Stimulation (VNS), a pacemaker-like device that helps reset the brain's electrical activity.
How does Fenfluramine work, and does it require special monitoring?
Fenfluramine interacts with specific serotonin receptors in the brain to stabilize electrical activity and reduce seizures. Because older versions of the drug were linked to heart issues, children taking it receive regular heart ultrasounds as a standard safety precaution.
Are there any gene therapies available for Dravet syndrome?
Newer disease-modifying therapies, such as antisense oligonucleotides (ASOs) and targeted gene therapies, are currently in development. Unlike standard drugs that just treat the electrical storm, these aim to address the underlying SCN1A genetic mutation directly.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Are any of my child's current medications on the 'do not use' list that could be worsening their seizures?
  2. 2.Based on my child's current seizure frequency, which of the 'Big Three' (Fenfluramine, Stiripentol, Cannabidiol) should we consider adding next?
  3. 3.What are the common side effects of Fenfluramine, and how do we monitor for potential heart valve issues?
  4. 4.If medications are not enough, at what point should we consider starting the Ketogenic Diet or Vagus Nerve Stimulation?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (25)
  1. 1

    Antiepileptic drugs for the treatment of infants with severe myoclonic epilepsy.

    Brigo F, Igwe SC, Bragazzi NL

    The Cochrane database of systematic reviews 2017; (5()):CD010483 doi:10.1002/14651858.CD010483.pub4.

    PMID: 28521067
  2. 2

    Pharmacotherapy for Dravet Syndrome.

    Wallace A, Wirrell E, Kenney-Jung DL

    Paediatric drugs 2016; (18(3)):197-208 doi:10.1007/s40272-016-0171-7.

    PMID: 26966048
  3. 3

    Recent Advances in the Drug Treatment of Dravet Syndrome.

    Wirrell EC, Nabbout R

    CNS drugs 2019; (33(9)):867-881 doi:10.1007/s40263-019-00666-8.

    PMID: 31549357
  4. 4

    Therapeutic advances in Dravet syndrome: a targeted literature review.

    Strzelczyk A, Schubert-Bast S

    Expert review of neurotherapeutics 2020; (20(10)):1065-1079 doi:10.1080/14737175.2020.1801423.

    PMID: 32799683
  5. 5

    Dravet syndrome diagnosed in adults.

    Dudley AM, Peña-Ceballos J, El-Naggar H, et al.

    Practical neurology 2026; (26(2)):124-132 doi:10.1136/pn-2025-004743.

    PMID: 41136202
  6. 6

    Dravet Syndrome: Diagnosis and Long-Term Course.

    Connolly MB

    The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 2016; (43 Suppl 3()):S3-8 doi:10.1017/cjn.2016.243.

    PMID: 27264139
  7. 7

    Influence of contraindicated medication use on cognitive outcome in Dravet syndrome and age at first afebrile seizure as a clinical predictor in SCN1A-related seizure phenotypes.

    de Lange IM, Gunning B, Sonsma ACM, et al.

    Epilepsia 2018; (59(6)):1154-1165 doi:10.1111/epi.14191.

    PMID: 29750338
  8. 8

    Genetic Landscape of SCN1A Variants in a Turkish Cohort with GEFS+ Spectrum and Dravet Syndrome.

    Türkyılmaz A, Tekin E, Yaralı O, Çebi AH

    Molecular syndromology 2022; (13(4)):270-281 doi:10.1159/000521330.

    PMID: 36158059
  9. 9

    Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens: A Randomized Clinical Trial.

    Nabbout R, Mistry A, Zuberi S, et al.

    JAMA neurology 2020; (77(3)):300-308 doi:10.1001/jamaneurol.2019.4113.

    PMID: 31790543
  10. 10

    Serotonin 5-HT4 receptors play a critical role in the action of fenfluramine to block seizure-induced sudden death in a mouse model of SUDEP.

    Tupal S, Faingold CL

    Epilepsy research 2021; (177()):106777 doi:10.1016/j.eplepsyres.2021.106777.

    PMID: 34601387
  11. 11

    Serotonin receptors in epilepsy: Novel treatment targets?

    Sourbron J, Lagae L

    Epilepsia open 2022; (7(2)):231-246 doi:10.1002/epi4.12580.

    PMID: 35075810
  12. 12

    Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial.

    Lagae L, Sullivan J, Knupp K, et al.

    Lancet (London, England) 2019; (394(10216)):2243-2254 doi:10.1016/S0140-6736(19)32500-0.

    PMID: 31862249
  13. 13

    An Update on Stiripentol Mechanisms of Action: A Narrative Review.

    Bacq A, Depaulis A, Castagné V, et al.

    Advances in therapy 2024; (41(4)):1351-1371 doi:10.1007/s12325-024-02813-0.

    PMID: 38443647
  14. 14

    Stiripentol: A Novel Antiseizure Medication for the Management of Dravet Syndrome.

    Buck ML, Goodkin HP

    The Annals of pharmacotherapy 2019; (53(11)):1136-1144 doi:10.1177/1060028019856008.

    PMID: 31167540
  15. 15

    Pharmacological considerations in the use of stiripentol for the treatment of epilepsy.

    Verrotti A, Prezioso G, Stagi S, et al.

    Expert opinion on drug metabolism & toxicology 2016; (12(3)):345-52 doi:10.1517/17425255.2016.1145657.

    PMID: 26890312
  16. 16

    Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.

    Devinsky O, Cross JH, Laux L, et al.

    The New England journal of medicine 2017; (376(21)):2011-2020 doi:10.1056/NEJMoa1611618.

    PMID: 28538134
  17. 17

    Anticonvulsant effect of cannabidiol in the pentylenetetrazole model: Pharmacological mechanisms, electroencephalographic profile, and brain cytokine levels.

    Vilela LR, Lima IV, Kunsch ÉB, et al.

    Epilepsy & behavior : E&B 2017; (75()):29-35 doi:10.1016/j.yebeh.2017.07.014.

    PMID: 28821005
  18. 18

    Cannabidiol anticonvulsant effect is mediated by the PI3Kγ pathway.

    Lima IVA, Bellozi PMQ, Batista EM, et al.

    Neuropharmacology 2020; (176()):108156 doi:10.1016/j.neuropharm.2020.108156.

    PMID: 32574650
  19. 19

    A Phase 1, Open-Label, Pharmacokinetic Trial to Investigate Possible Drug-Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects.

    Morrison G, Crockett J, Blakey G, Sommerville K

    Clinical pharmacology in drug development 2019; (8(8)):1009-1031 doi:10.1002/cpdd.665.

    PMID: 30791225
  20. 20

    Efficacy of the ketogenic diet in patients with Dravet syndrome: A meta-analysis.

    Wang YQ, Fang ZX, Zhang YW, et al.

    Seizure 2020; (81()):36-42 doi:10.1016/j.seizure.2020.07.011.

    PMID: 32712377
  21. 21

    The Ketogenic and Modified Atkins Diet Therapy for Children With Refractory Epilepsy of Genetic Etiology.

    Jagadish S, Payne ET, Wong-Kisiel L, et al.

    Pediatric neurology 2019; (94()):32-37 doi:10.1016/j.pediatrneurol.2018.12.012.

    PMID: 30803845
  22. 22

    Eating habits and behaviors in children with Dravet syndrome: A case-control study.

    Laliberté A, Siafa L, Soufi A, et al.

    Epilepsia 2025; (66(1)):e1-e6 doi:10.1111/epi.18179.

    PMID: 39503590
  23. 23

    Long-term seizure reduction with vagus nerve stimulation in Dravet syndrome.

    Bajaj S, Ivaniuk A, Bruenger T, et al.

    Developmental medicine and child neurology 2026; doi:10.1111/dmcn.70127.

    PMID: 41521608
  24. 24

    Use of social media to assess the effectiveness of vagal nerve stimulation in Dravet syndrome: A caregiver's perspective.

    Ali R, Elsayed M, Kaur M, et al.

    Journal of the neurological sciences 2017; (375()):146-149 doi:10.1016/j.jns.2017.01.057.

    PMID: 28320117
  25. 25

    Emerging Genetic Therapies in Epilepsy.

    Sullivan J, Hood V

    Seminars in neurology 2025; (45(2)):298-302 doi:10.1055/a-2544-1530.

    PMID: 39993433

This page provides educational information on Dravet syndrome treatments and contraindicated medications. Always consult your pediatric epileptologist before adding, changing, or stopping your child's medication regimen.

Get notified when new evidence is published on Dravet syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.